Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQUIRE: Necitumumab in Advanced Squamous NSCLC
NCT00981058Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2010
- Primary completion
- Jun 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of necitumumab in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival up to 31 Months. Started Jan 2010; status: completed.
02
Drugs
necitumumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT00981058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981058.